Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medx Health Corp V.MDX

Alternate Symbol(s):  MDXHF

MedX Health Corp. is a medical device and software company. It develops and manufactures skin-related screening tools and phototherapy devices for pain relief and tissue repair. It focuses on skin health with its SIAscopy on DermSecure telemedicine platform, utilizing its SIAscopy technology. SIAscopy is a medical device technology that is used to scan skin for suspicious moles and lesions and, including DermSecure, its telemedicine software application, and phototherapeutic medical devices, which use light energy in lower-level laser and light-emitting diode to provide treatment of pain and tissue damage in the rehabilitation market. Its products SIAMETRICS, SIMSYS, and MoleMate include hand-held devices that use patented technology utilizing light and its remittance to view up to two millimeters beneath suspicious moles and lesions in a pain free, non-invasive manner. Its SIAscopy on DermSecure telemedicine platform enables the Web-based operation of its SIAscopy scanning technology.


TSXV:MDX - Post by User

Post by PrairieInvestoron May 03, 2022 6:06am
303 Views
Post# 34650211

Q4 2021 Take-aways

Q4 2021 Take-awaysPositive: Revenue was strong. $212K revenue is the highest since Q3 2019. Gross profit highest it has been in over 2 years. Cost of revenue considerably lower in Q4 compared to Q1-Q3. Top line growth should be the primary focus of this company while controlling spend. Siascopy revenues highest they have been since 2019, with mention that much of that was service rev and not hardware rev.

Negative: There are many...cash is a major concern moving forward. CEO and CFO resigned in Q1 2022. 

This company needs to be transparent moving forward. Set realistic short and long terms goals and how the company is going to achieve those goals. Then update investors on how you are progressing toward those goals. Each news release can tie back into the goals previously set. Fundamental stuff really. 

<< Previous
Bullboard Posts
Next >>